EP300 and neoplasm: In an effort to determine if E1A could augment anti-tumor-specific T cell responses to OVA, we first generated MCA-205 tumor lines (see Materials and Methods) that expressed a slightly truncated OVA 3–383 (MCA-205-OVA), a fusion protein of full length E1A and OVA3–383 (MCA-205-E1A-OVA) or a fusion protein of mutant E1A lacking amino acids 48–60, which results in the inability of E1A to bind p300 (E1A-Δp300) and OVA3–383 (MCA-205-E1A-Δp300-OVA).